Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.
